Kornitzer Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $14.1M | Sell |
44,532
-15,810
| -26% | -$3.73M | 0.29% | 76 |
|
|
2026
Q1 | $12M | Hold |
60,342
| – | – | 0.26% | 85 |
|
|
2025
Q4 | $11.4M | Sell |
60,342
-30,825
| -34% | -$5.92M | 0.24% | 97 |
|
|
2025
Q3 | $16.1M | Hold |
91,167
| – | – | 0.32% | 71 |
|
|
2025
Q2 | $10.4M | Sell |
91,167
-44,315
| -33% | -$4.74M | 0.21% | 126 |
|
|
2025
Q1 | $14.2M | Hold |
135,482
| – | – | 0.29% | 86 |
|
|
2024
Q4 | $14.5M | Hold |
135,482
| – | – | 0.28% | 92 |
|
|
2024
Q3 | $13.6M | Hold |
135,482
| – | – | 0.25% | 116 |
|
|
2024
Q2 | $11.4M | Hold |
135,482
| – | – | 0.22% | 134 |
|
|
2024
Q1 | $9.9M | Hold |
135,482
| – | – | 0.18% | 172 |
|
|
2023
Q4 | $9.68M | Hold |
135,482
| – | – | 0.19% | 176 |
|
|
2023
Q3 | $8.12M | Hold |
135,482
| – | – | 0.17% | 194 |
|
|
2023
Q2 | $9.77M | Hold |
135,482
| – | – | 0.19% | 174 |
|
|
2023
Q1 | $9.97M | Buy |
135,482
+28,730
| +27% | +$2.04M | 0.2% | 164 |
|
|
2022
Q4 | $7.13M | Sell |
106,752
-94,732
| -47% | -$6.16M | 0.14% | 218 |
|
|
2022
Q3 | $10.8M | Sell |
201,484
-151,852
| -43% | -$8.93M | 0.23% | 144 |
|
|
2022
Q2 | $19.7M | Sell |
353,336
-133,049
| -27% | -$7.55M | 0.39% | 72 |
|
|
2022
Q1 | $34.1M | Hold |
486,385
| – | – | 0.56% | 39 |
|
|
2021
Q4 | $46.9M | Hold |
486,385
| – | – | 0.7% | 23 |
|
|
2021
Q3 | $42.3M | Sell |
486,385
-52,539
| -10% | -$4.06M | 0.65% | 25 |
|
|
2021
Q2 | $44.1M | Sell |
538,924
-109,930
| -17% | -$9.14M | 0.66% | 26 |
|
|
2021
Q1 | $61.7M | Sell |
648,854
-58,374
| -8% | -$5.52M | 0.99% | 5 |
|
|
2020
Q4 | $43.9M | Buy |
707,228
+60,979
| +9% | +$3.48M | 0.74% | 23 |
|
|
2020
Q3 | $38.4M | Buy |
646,249
+73,048
| +13% | +$4.98M | 0.75% | 24 |
|
|
2020
Q2 | $40M | Buy |
573,201
+348,500
| +155% | +$22.1M | 0.81% | 17 |
|
|
2020
Q1 | $10.2M | Buy |
224,701
+54,310
| +32% | +$3.08M | 0.24% | 143 |
|
|
2019
Q4 | $11.1M | Sell |
170,391
-18,383
| -10% | -$1.23M | 0.2% | 161 |
|
|
2019
Q3 | $11.7M | Buy |
188,774
+11,221
| +6% | +$704K | 0.21% | 146 |
|
|
2019
Q2 | $12.6M | Sell |
177,553
-7,518
| -4% | -$554K | 0.22% | 141 |
|
|
2019
Q1 | $14.5M | Buy |
185,071
+36,362
| +24% | +$2.75M | 0.26% | 129 |
|
|
2018
Q4 | $12.6M | Buy |
148,709
+44,783
| +43% | +$4.77M | 0.25% | 131 |
|
|
2018
Q3 | $17.8M | Sell |
103,926
-15,068
| -13% | -$2.27M | 0.28% | 125 |
|
|
2018
Q2 | $15.4M | Sell |
118,994
-1,592
| -1% | -$178K | 0.26% | 126 |
|
|
2018
Q1 | $12.4M | Sell |
120,586
-30,713
| -20% | -$3.04M | 0.21% | 142 |
|
|
2017
Q4 | $12.9M | Sell |
151,299
-6,877
| -4% | -$596K | 0.22% | 139 |
|
|
2017
Q3 | $13.4M | Sell |
158,176
-26,979
| -15% | -$2.14M | 0.23% | 133 |
|
|
2017
Q2 | $14M | Buy |
185,155
+84,062
| +83% | +$5.88M | 0.25% | 130 |
|
|
2017
Q1 | $6.67M | Buy |
101,093
+817
| +0.8% | +$53.7K | 0.12% | 227 |
|
|
2016
Q4 | $6.36M | Sell |
100,276
-8,504
| -8% | -$537K | 0.12% | 225 |
|
|
2016
Q3 | $6.93M | Buy |
+108,780
| New | +$7.99M | 0.12% | 222 |
|
Other funds holding LGND
JT
CAM
Kornitzer Capital Management's LGND Position: Q2 2026 in Review
Kornitzer Capital Management reduced its Ligand Pharmaceuticals (LGND) stake by 26% in Q2 2026, selling an estimated $3.73M and leaving 44,532 shares worth $14.1M. The position accounts for 0.29% of the portfolio, ranked #76.
Kornitzer Capital Management first reported a position in LGND in Q3 2016 and has held it in 40 quarters since. The position peaked at $61.7M in Q1 2021. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- Kornitzer Capital Management held 44,532 shares of Ligand Pharmaceuticals worth $14.1M as of Q2 2026.
- Kornitzer Capital Management sold 15,810 Ligand Pharmaceuticals shares in Q2 2026, an estimated $3.73M.
- Ligand Pharmaceuticals made up 0.29% of Kornitzer Capital Management's portfolio in Q2 2026, its #76 holding.
- Kornitzer Capital Management first reported a position in Ligand Pharmaceuticals in Q3 2016 and has held it in 40 quarters since.
- Kornitzer Capital Management's Ligand Pharmaceuticals position peaked at $61.7M in Q1 2021.
- 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on Kornitzer Capital Management's 13F filing for Q2 2026, filed 31 Jul 2026.